Irvine Scientific introduces xeno-free T cell growth medium

By Dan Stanton

- Last updated on GMT

Image: iStock/cgtoolbox
Image: iStock/cgtoolbox

Related tags Bacteria

Irvine Scientific has launched what it says is the first available chemically-defined, animal component-free medium for T cell culture.

Part of the California, US-headquartered firm’s range of animal serum-free growth media, the PRIME-XV T Cell CDM media has been introduced for manufacturers looking to aid consistency in the growth of T cells.

According to the firm this is the first T cell specific media to be both chemically-defined and animal component-free.

The formulation meets the industrial cell culture/biopharmaceutical industry definition of chemically-defined and animal component-free at the tertiary level,” ​Jessie H.-T. Ni, CSO at Irvine Scientific told us.

“T-cell mediated immunotherapy for treating various diseases requires ex vivo production of specific T cell subsets to high cell densities, without loss of desired T cell phenotypes and functionality.”

Undefined media components such as cytokines contained in serum may impact the efficiency of generating these desired T cell populations, they explained, while a media which is not chemically defined may contain undefined and potentially inhibitory components that could affect the efficiency and consistency necessary for immunotherapy applications.

Fetal bovine serum (FBS) is currently deemed the “gold-standard”​ for CAR T cells due to it having a content of embryonic growth promoting factors and  a low level of antibodies, but – as a by-product from the dairy industry – there have been concerns about its poor characterization and the potential for transmitting bovine diseases.

“When compared with media supplemented with three different lots of bovine serum (at 10% serum), PRIME-XV T Cell CDM delivered consistent performance and showed a 30% – 400% improvement in expansion of human peripheral blood-derived CD3+​ T cells than the media supplemented with bovine-derived serum,”​ Ni told us.

“This dramatic difference in expansion rates highlights how variable the performance can be between lots of serum.”

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more